Emergent BioSolutions shares dropped 20% after-hours as FY2026 and Q1 revenue guidance missed consensus estimates. Although the company announced a $50 million buyback and new contracts, the weak outlook overshadowed these positives. Naloxone sales fell 41% due to competition, while anthrax product revenue rose.